SOPHiA Genetics SA Stock

$3.61

4.94% today

Nasdaq, Aug 22, 10:00 pm CET

ISIN

CH1125843347

Symbol

SOPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Technology

Overview Dividends Analysts Charts News Strategies

SOPHiA Genetics SA Stock price

$3.61

-13.15 78.46% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.17 4.94%

ISIN

CH1125843347

Symbol

SOPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Technology

Key metrics

Basic

Market capitalization

$232.5m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.3 | 3.1

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

62.1%

Return on Equity

-64.8%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$69.7m | $75.7m

EBITDA

$-58.2m | $-37.1m

EBIT

$-67.3m | $-63.8m

Net Income

$-73.4m | -

Free Cash Flow

$-45.7m

Growth (TTM | estimate)

Revenue

7.3% | 16.1%

EBITDA

4.6% | 36.0%

EBIT

2.8% | 4.1%

Net Income

-9.9% | -

Free Cash Flow

17.8%

EPS

$-1.1

FCF per Share

Short interest

0.0%

Employees

423

Rev per Employee

$150.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

SOPHiA Genetics SA Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a SOPHiA Genetics SA forecast:

10x Buy

91%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a SOPHiA Genetics SA forecast:

Buy

91%

Hold

Analyst Estimates with Stock Price Targets

Financial data from SOPHiA Genetics SA

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	70 70	7% 7% 100%
- Direct Costs	22 22	9% 9% 32%
Gross Profit	47 47	6% 6% 68%
- Selling and Administrative Expenses	80 80	2% 2% 115%
- Research and Development Expense	35 35	4% 4% 50%
EBITDA	-58 -58	5% 5% -83%
- Depreciation and Amortization	9.17 9.17	11% 11% 13%
EBIT (Operating Income) EBIT	-67 -67	3% 3% -97%
Net Profit	-73 -73	10% 10% -105%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

SOPHiA Genetics SA Stock News

Neutral

Seeking Alpha

●

17 days ago

SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants George A. Cardoza - Executive VP & CFO Jurgi Camblong - Co-Founder, CEO & Director Kellen Sanger - Head of Strategy and Investor Relations Ross Jordan Muken - President Conference Call Participants Conor Noel McNamara - RBC Capital Markets, Research Division Daniel Gregory Brennan -...

Neutral

PRNewsWire

●

17 days ago

SOPHiA GENETICS Reports Second Quarter 2025 Results

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-year Gross margin was 67.0% on a reported basis and 74.4% on an adjusted basi...

Neutral

PRNewsWire

●

17 days ago

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficac...

More SOPHiA Genetics SA News

Company Profile

SOPHiA GENETICS SA is a healthcare technology company, which establishes the practice of data driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Head office	Switzerland
CEO	Jurgi Camblong
Employees	423
Founded	2011
Website	www.sophiagenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now